{
    "summary": "The Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2025 (H.R. 1632) amends the Federal Food, Drug, and Cosmetic Act to allow reciprocal marketing approval for certain drugs, biological products, and devices approved in other countries (specifically those on a list under section 802(b)(1) or the UK). The bill aims to expedite the availability of potentially life-saving treatments in the U.S. by streamlining the approval process. It outlines criteria for eligibility, the Secretary's role in granting or denying approval, and a process for Congressional oversight.",
    "tags": [
        "Healthcare",
        "Consumer protection",
        "Public safety",
        "Healthcare access",
        "Federal agency action"
    ],
    "category": "Healthcare & Public Health"
}